Session Information
-
WCLC 2018
19th World Conference on Lung Cancer
Conference Program for the 19th World Conference on Lung Cancer in Toronto, Canada
Download PDF of the Abstract Book: Click Here.
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2391
September 23 Sun
Sep 23 Monday
September 24 Mon
Sep 24 Tuesday
September 25 Tue
Sep 25 Wednesday
September 26 Wed
Sep 26
-
+
MA04 - Novel Approaches with IO
- 13:30 - 15:00
- 9/24/2018
- Location: Room 107
- Type: Mini Oral Abstract Session
- Track: Immunooncology
-
+
MA04.01 - Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts
13:30 - 13:35 | Presenter: Victor Moreno | Author(s): Marta Gil-Martin, Melissa L. Johnson, Raid Aljumaily, Maria Pilar Lopez-Criado, Donald W Northfelt, Marka Crittenden, Salma Jabbour, Lee Rosen, Emiliano Calvo, Kyriakos P Papadopoulos, Pilar Garrido, Asuncion Hervás Morón, Petra Rietschel, Kosalai Mohan, Jingjin Li, Elizabeth Stankevich, Minjie Feng, Israel Lowy, Matthew Fury
- Abstract
Loading...
-
+
P3.04 - Immunooncology (Not CME Accredited Session)
- 12:00 - 13:30
- 9/26/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P3.04-24 - EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
12:00 - 13:30 | Presenter: Naiyer A Rizvi | Author(s): Sue Lee, Paul Curtis, Wilson Caldwell, Bo Gao, Petra Rietschel
- Abstract
Loading... -
+
P3.04-25 - EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50%
12:00 - 13:30 | Presenter: Naiyer A Rizvi | Author(s): Sue Lee, Paul Curtis, Wilson Caldwell, Bo Gao, Petra Rietschel
- Abstract
Loading... -
+
P3.04-26 - EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%
12:00 - 13:30 | Presenter: Naiyer A Rizvi | Author(s): Sue Lee, Paul Curtis, Wilson Caldwell, Bo Gao, Petra Rietschel
- Abstract
Loading...